- Docket No.
- 23-35294
- Appellate Court
- Ninth Circuit
Goal
- Review district court's denial of motion to intervene by several states
Issues
Case History
Litigation Content
Why this Matters:
The Plaintiffs allege that the Food and Drug Administration (FDA) violated the Administrative Procedure Act and the Equal Protection Clause of the U.S. Constitution by subjecting mifepristone to burdensome requirements that makes the drug extremely difficult to access and prescribe. Ensuring that individuals have access to safe and effective medication abortions enables patients to receive necessary reproductive health care.
Potential Impact:
Unnecessary restrictions on safe and effective drugs can create obstacles for doctors to promote medically appropriate care and jeopardize the health and safety of patients seeking medication for abortion services.
14 Major Filings
- APPELLANTS' PETITION FOR REHEARING EN BANC (Sep 9, 2024)
- OPINION (Jul 27, 2024)
- SUPPLEMENTAL BRIEF FOR FEDERAL APPELLEES (Jun 27, 2024)
- SUPPLEMENTAL BRIEF OF PLAINITFFS-APPELLEES (Jun 27, 2024)
- SUPPLEMENTAL BRIEF OF APPELLANTS (Jun 27, 2024)
- ORDER (Jun 13, 2024)
- ORDER (Jun 13, 2024)
- ARGUED AND SUBMISSION DEFERRED TO SIDNEY R. THOMAS, M. MARGARET MCKEOWN and MORGAN B. CHRISTEN (Mar 13, 2024)
- APPELLANTS' CITATION OF SUPPLEMENTAL AUTHORITIES (Feb 6, 2024)
- APPELLEES' CITATION OF SUPPLEMENTAL AUTHORITIES (Jan 19, 2024)
- REPLY BRIEF OF APPELLANTS (Nov 30, 2023)
- BRIEF OF PLAINTIFFS-APPELLEES (Oct 10, 2023)
- BRIEF FOR FEDERAL APPELLEES (Oct 10, 2023)
- OPENING BRIEF OF APPELLANT (Aug 7, 2023)